On November 28, 2008 Cancer Research Technology Limited (CRT), the oncology-focused development and commercialisation company, and the technology development specialists The Technology Partnership plc (TTP) reported they have agreed to join forces to progress new lens-free imaging equipment called CyMap (Press release, Cancer Research Technology, NOV 28, 2008, View Source [SID1234523361]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

CyMap is able to detect a range of particle types in a solution and holds the potential to be used in highly cost-effective medical diagnostics systems* in hospitals, doctors surgeries and research laboratories to detect, quantify and analyse medical samples such as blood or bacteria.

This technology is based on the principle that when illuminated using a simple light source, ‘items’ such as cells or pathogens in a sample create light diffraction** and interference patterns that can be recorded by a charge-coupled device (CCD) – a type of digital camera – and then analysed using computer algorithms. This will enable scientists to count the number of ‘items’ in a sample, and also to monitor changes over time, such as location, movement and division of cells. This information will be useful in helping scientists understand cell division and cell movement, which are important in some normal processes such as wound healing, and in some diseases including cancer.

In the diagnostics field, CyMap may also be developed to monitor bacterial contamination, the presence of other pathogens, or to count red and white blood cells. One of the other advantages of CyMap technology is that it can be easily miniaturised and integrated with microfluidic systems – and it may also have other wider research applications as well.

Professor Borivoj Vojnovic, one of the inventors of the technology at the Gray Institute for Radiation Oncology and Biology, University of Oxford, (GIROB) said: "This new generation of imaging technology will hopefully be much smaller, cheaper and easier to use than the existing alternatives which are usually only available to scientists and pathologists in larger well equipped bioscience laboratories. We envisage CyMap working well as a hand-held device which should make the equipment accessible and affordable for more people working in cancer and other health related disciplines across the world."

The technology was developed by members of the Optical Biochips Consortium, at GIROB, Cardiff University and Bangor University. This Consortium was backed by funding*** from Research Councils UK, which includes the Biotechnology and Biological Science Research Council and the Engineering Physical Sciences Research Council.

The intellectual property arising from this laboratory-based research has been assigned to CRT which has filed a patent to protect the academic work. Under the terms of the agreement announced today, CRT has awarded TTP an exclusive option to license and develop the CyMap technology. TTP will seek other commercial partners to develop and bring to market a range of applications based on CyMap, either by direct licensing arrangements or through co-development partnerships. CRT and TTP will share the revenues arising from any future development and sales of the technology.

Paul Galluzzo, consulant at TTP, said: "We specialise in commercialising technology that holds the potential to make a real difference in sectors such as clinical and consumer diagnostics, drug discovery, consumer products, digital printing, and communications. We frequently work in partnership with the scientists who made the discovery to bring exciting concepts to the marketplace. CyMap is genuinely innovative and we believe it has great commercial potential, for example to enable new diagnostic platforms, and to introduce imaging capability to products where imaging is currently too expensive. The next stage will be to develop the technology for a range of specific product areas."

Dr Phil L’Huillier, CRT’s director of business management said: "We believe this technology is very exciting and it’s great to be able to see it progressed in today’s deal. We hope CyMap will help understand and predict what is happening to patients at a basic biological level. This could, one day, have an impact on treatments and how they are delivered. CyMap technology has the potential to be cheaper, more compact and simpler to use which will hopefully prevent doctors from having to send as many samples to laboratories for analysis and enable quicker and easier monitoring of the samples. Only time will tell if this early stage promise pays off but we will watch its progress eagerly."